Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
Document Type
Journal Article
Publication Date
7-1-2019
Journal
The lancet oncology
Volume
20
Issue
7
Inclusive Pages
1011-1022
DOI
10.1016/S1470-2045(19)30277-3
APA Citation
Fangusaro, J., Onar-Thomas, A., Young Poussaint, T., Wu, S., Ligon, A., Lindeman, N., Banerjee, A., Packer, R., Kilburn, L., Goldman, S., Pollack, I., Qaddoumi, I., Jakacki, R., Fisher, P., Dhall, G., Baxter, P., Kreissman, S., Stewart, C., Jones, D., Pfister, S., Vezina, G., Stern, J., Panigrahy, A., Patay, Z., Tamrazi, B., Jones, J., Haque, S., Enterline, D., Cha, S., Fisher, M., Doyle, L., Smith, M., Dunkel, I., & Fouladi, M. (2019). Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.. The lancet oncology, 20 (7). http://dx.doi.org/10.1016/S1470-2045(19)30277-3
Peer Reviewed
1